Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChristopher C. Thompson, MD, MSc

About this trial

The objective of the study is to investigate the treatment of marginal ulcers with Low Thermal plasma in an endoscopic setting. By a treatment of the ulcerated areas with argon plasma with low power settings (\~ 1 W) we hypothesize that the size of the ulcers will shrink, and the healing is accelerated compared to standard of care alone. Patients will benefit from this minimally invasive approach compared to a much more invasive surgical approach that comes with higher risks and hospital stay length time. From a societal and scientific perspective, this study aims to extend the well-documented clinical benefits of plasma technology - from external wound healing to internal ulcer treatment - within an endoscopic framework. The success of this study could pave the way for broader applications of LTP in the treatment of other endoscopically accessible conditions such as peptic ulcers, duodenal ulcers and esophageal ulcers. This advancement has the potential not only to improve patient outcomes through less invasive methods, but also to position LTP as a cornerstone in the future of gastroenterological wound management strategies.

Eligibility criteria

Qualifiers

Subjects aged 18 years and above, inclusive of both males and females.

Patients with a history of Roux-en-Y gastric bypass (RYGB) presenting symptoms indicative of marginal ulcers (MUs) such as abdominal pain, nausea, vomiting, gastrointestinal bleeding, or dysphagia.

Subjects must be scheduled for an EGD for the evaluation of these symptoms.

Marginal ulcers confirmed during the initial EGD.

Disqualifiers

Inability to provide informed consent.

Unwillingness to undergo repeated endoscopies.

Inability or unwillingness to comply with the SOC.

Current use of systemic antibiotics.

Trial design

Treatments tested in this trial

  • Low Thermal Plasma (LTP) Treatment
  • Standard of Care Ulcer Treatment (typically PPI Administration)

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Christopher C. Thompson, MD, MSc

Lead sponsor

Brigham and Women's Hospital

Sponsor institution

Erbe USA Incorporated

Collaborator